Lupin Ramps Up Strategy to Counter U.S. Tariff Threat, Posts 52% Profit Surge

Mumbai, August 7, 2025 — Indian pharmaceutical giant Lupin is drawing up a multi-pronged strategy to navigate the looming threat of U.S. tariffs, while celebrating a robust 52% year-on-year surge in its Q1 net profit.

 

The company reported a profit after tax (PAT) of ₹1,221 crore for the quarter ended June 30, 2025, up from ₹805 crore in the same period last year. Revenues rose to ₹6,163 crore, reflecting a near 12% growth over ₹5,514 crore in Q1 FY25.

 

A large part of this growth came from the United States, which contributed 39% to Lupin’s Q1 revenues. India, Lupin’s second-largest market, contributed 34%.

 

U.S. Tariff Threat Sparks Strategic Recalibration

Addressing analysts post-results, CEO Vinita Gupta said the company is proactively preparing for the uncertain outcome of the ongoing Section 232 investigation in the U.S., which could potentially impose tariffs of up to 250% on imports — including pharmaceutical products.

“While tariffs in the 10–15% range are manageable, anything beyond that would significantly impact affordability for U.S. patients,” Gupta warned.

To mitigate this risk, Lupin is accelerating tech transfers to its U.S.-based manufacturing units and exploring intellectual property (IP) shifts for high-value drugs. The company is also evaluating price increases on certain products where market conditions permit flexibility.

 

“Lupinhttp://Lupin is deeply committed to ensuring the affordability of medicines, especially in the U.S.,” added Ramesh Swaminathan, Executive Director and Global CFO. “But high tariffs would harm patients and disrupt the generic medicine ecosystem.”

Momentum Builds for Blockbuster Drugs Like Semaglutide

 

Lupin is preparing to be among the first wave of companies manufacturing semaglutide — a blockbuster anti-diabetic and weight loss drug — as it goes off patent early next year. This strategic move could unlock a major growth channel in the coming quarters.

 

Managing Director Nilesh Gupta emphasized the company’s sharpened focus on compliance, innovation, and technology, saying: “These pillars position us to unlock sustainable growth in the years ahead.”

 

Solid Q1 Performance Across Markets

 

Lupin’s U.S. business clocked ₹2,404 crore in Q1 sales — up 24.3% over the same period last year. In India, sales reached ₹2,089 crore, marking a 7.8% rise year-on-year. The company also ramped up R&D investments to ₹484 crore this quarter, up from ₹350 crore in Q1 FY25, signaling its long-term innovation commitment.

 

Outlook: Resilience Amid Global Trade Tensions

 

As geopolitical and trade uncertainties loom large, Lupin’s leadership remains confident in its ability to adapt. With a focus on diversification, local manufacturing, and high-value therapies, the company is building resilienceo its global operations.

 

Related Posts

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

MEERUT/SHIMLA: An illegal pharmaceutical factory allegedly manufacturing counterfeit medicines used to treat epilepsy, diabetes, typhoid and other ailments using substances such as chalk and lactose was busted in Himachal Pradesh’s…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital